C07K16/3053 - page 2 - CPC Classification Index

#301

20170190776

2017-07-06

Methods for manipulating phagocytosis mediated by CD47

#302

20170174786

2017-06-22

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

#303

20170174774

2017-06-22

Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment

#304

20170174773

2017-06-22

Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer

#305

20170174771

2017-06-22

Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

#306

20170174744

2017-06-22

Method for treating melanoma

#307

20170166653

2017-06-15

Antibodies for epidermal growth factor receptor 3 (HER3)

#308

20170166641

2017-06-15

Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer

#309

20170165383

2017-06-15

Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins

#310

20170152322

2017-06-01

Pan-HER antibody composition

#311

20170151341

2017-06-01

Site specific HER2 antibody drug conjugates

#312

20170143827

2017-05-25

Compositions comprising a combination of nivolumab and ipilimumab

#313

20170137533

2017-05-18

Anti-DLL3 antibodies and drug conjugates for use in melanoma

#314

20170129964

2017-05-11

Uses of monoclonal antibody 8H9

#315

20170121420

2017-05-04

ANTI-IL1RAP ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND IL1RAP AND CD3, AND USES THEREOF

#316

20170119883

2017-05-04

Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells

#317

20170114141

2017-04-27

Bispecific antibodies specific for OX40

#318

20170114137

2017-04-27

ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS

#319

20170112928

2017-04-27

Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase

#320

20170112894

2017-04-27

Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment

#321

20170107284

2017-04-20

POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS

#322

20170106048

2017-04-20

Combination of CD95/CD95L inhibition and Cancer Immunotherapy

#323

20170101479

2017-04-13

GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND USE THEREOF

#324

20170101464

2017-04-13

Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature

#325

20170100425

2017-04-13

Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment

#326

20170100424

2017-04-13

β-glucan methods and compositions that affect the tumor microenvironment

#327

20170088627

2017-03-30

Method of treating cancer with a combination of an anti-CCR4 antibody and a 4-1BB agonist

#328

20170074867

2017-03-16

Direct immunohistochemistry assay

#329

20170072065

2017-03-16

Anti-EGFR antibodies and antibody drug conjugates

#330

20170044259

2017-02-16

Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof

#331

20170044256

2017-02-16

Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibitors

#332

20170042995

2017-02-16

Combination vaccine devices and methods of killing cancer cells

#333

20170037146

2017-02-09

Mutated antibody of fully humanized HER2 antibody, and encoding gene and use thereof

#334

20170037127

2017-02-09

Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors

#335

20170037110

2017-02-09

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

#336

20170037107

2017-02-09

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

#337

20170037098

2017-02-09

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

#338

20170037097

2017-02-09

Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers

#339

20170037096

2017-02-09

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

#340

20170037095

2017-02-09

Method for treating cancer with an activated T lymphocyte that selectively recognizes a cancer cell consisting of specific peptide

#341

20170037094

2017-02-09

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

#342

20170037093

2017-02-09

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

#343

20170037092

2017-02-09

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

#344

20170029525

2017-02-02

ANTIBODIES TO HUMAN B7X FOR TREATMENT OF METASTATIC CANCER

#345

20170029516

2017-02-02

Anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies and uses thereof

#346

20170029505

2017-02-02

MULTIMERIC FC PROTEINS

#347

20170022274

2017-01-26

T-cell redirecting bispecific antibodies for treatment of disease

#348

20170022273

2017-01-26

Antibody therapeutics that bind LAG3

#349

20170015757

2017-01-19

Anti-fibulin-3 antibodies and uses thereof

#350

20170008976

2017-01-12

Anti-metalloprotease antibody for diagnosis and treatment of cancers

#351

20170008969

2017-01-12

Antibodies against glioma biomarkers

#352

20170008963

2017-01-12

Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor

#353

20170002087

2017-01-05

Methods of enhancing anti-tumor immunity by administering antibodies to the CCRL2 chemerin receptor

#354

20170002085

2017-01-05

Methods of treating hedgehog-related diseases with an anti-LGR5 antibody

#355

20170002046

2017-01-05

PROTEINS COMPRISING BINDING REGIONS, SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS, AND CARBOXY-TERMINAL, ENDOPLASMIC RETICULUM LOCALIZATION SIGNAL MOTIFS

#356

20160376328

2016-12-29

PROTEINS COMPRISING AMINO-TERMINAL PROXIMAL SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS AND CELL-TARGETING IMMUNOGLOBULIN-TYPE BINDING REGIONS

#357

20160369003

2016-12-22

Antibody drug conjugates (ADC) that bind to 158P1D7 proteins

#358

20160355604

2016-12-08

Cancer therapy using CLDN6 target-directed antibodies in vivo

#359

20160340407

2016-11-24

COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF MELANOMA USING PD-L1 ISOFORMS

#360

20160340399

2016-11-24

Tumor necrosis factor (TNF) family ligand trimer-containing antigen binding molecules

#361

20160333110

2016-11-17

Anti-human TROP-2 antibody having an antitumor activity in vivo

#362

20160333083

2016-11-17

Targeting CLPTM1L for treatment and prevention of cancer

#363

20160319036

2016-11-03

Multispecific domain exchanged common variable light chain antibodies

#364

20160311919

2016-10-27

Antibodies Directed To GPNMB And Uses Thereof

#365

20160304607

2016-10-20

COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTIBODY

#366

20160303253

2016-10-20

Antibody-SN-38 immunoconjugates with a CL2A linker

#367

20160297890

2016-10-13

Anti-TROP2 antibody-drug conjugate

#368

20160297889

2016-10-13

Pharmaceutical composition for treatment and/or prevention of cancer

#369

20160289340

2016-10-06

Compositions and methods for treatment and detection of cancers

#370

20160289307

2016-10-06

Anti-S100A7 antibodies for the treatment and diagnosis of cancer

#371

20160280794

2016-09-29

Compositions and methods relating to universal glycoforms for enhanced antibody efficacy

#372

20160274121

2016-09-22

Cancer markers and methods of use thereof

#373

20160263207

2016-09-15

Therapeutic composition for treatment of glioblastoma

#374

20160257760

2016-09-08

Conjugated antibodies against LY75 for the treatment of cancer

#375

20160243192

2016-08-25

ANTIBODY DEPENDENT EXOSOME THERAPY

#376

20160237159

2016-08-18

METHODS AND COMPOSITIONS FOR REGULATORY T-CELL ABLATION

#377

20160216269

2016-07-28

Anti-SOX10 antibody systems and methods

#378

20160208014

2016-07-21

Pharmaceutical composition for treatment and prevention of cancers

#379

20160208009

2016-07-21

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

#380

20160207990

2016-07-21

Antibodies to endoplasmin and their use

#381

20160206764

2016-07-21

Monoclonal antibody and derivatives

#382

20160200819

2016-07-14

Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

#383

20160200816

2016-07-14

Methods of manipulating phagocytosis mediated by CD47

#384

20160185858

2016-06-30

Humanized antibodies to LIV-1 and use of same to treat cancer

#385

20160184399

2016-06-30

COMBINED PHARMACEUTICAL COMPOSITION

#386

20160176980

2016-06-23

T-cell redirecting bispecific antibodies for treatment of disease

#387

20160176978

2016-06-23

Methods of manipulating phagocytosis mediated by CD47

#388

20160176976

2016-06-23

Methods of manipulating phagocytosis mediated by CD47

#389

20160176968

2016-06-23

T-Cell Redirecting Bispecific Antibodies for Treatment of Disease

#390

20160175450

2016-06-23

Drug delivery of temozolomide for systemic based treatment of cancer

#391

20160168211

2016-06-16

Antibody multimerization technologies

#392

20160159913

2016-06-09

Binding molecules specific for HER3 and uses thereof

#393

20160145354

2016-05-26

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

#394

20160145350

2016-05-26

Antibodies against CD73

#395

20160144029

2016-05-26

Anti-ErbB3 antibodies and uses thereof

#396

20160136308

2016-05-19

Methods and apparatuses for the localization and treatment of disease such as cancer

#397

20160130347

2016-05-12

Fc-free antibodies comprising two fab-fragments and methods of use

#398

20160115242

2016-04-28

Anti-CSPG4 fusions with interferon for the treatment of malignancy

#399

20160108123

2016-04-21

Antibody molecules to PD-L1 and uses thereof

#400

20160102151

2016-04-14

Compositions and methods for treatment and detection of cancers

#401

20160089435

2016-03-31

PAN-HER ANTIBODY COMPOSITION

#402

20160083477

2016-03-24

Removal of Cancer Cells by Circulating Virus-Specific Cytotoxic T-Cells Using Cancer Cell Targeted MHC Class 1 Compromising Multi-Function Proteins

#403

20160082082

2016-03-24

USE OF THERAPEUTIC PEPTIDES FOR THE TREATMENT AND PREVENTION OF CANCER

#404

20160075785

2016-03-17

Bispecific T cell activating antigen binding molecules

#405

20160067314

2016-03-10

COMPOSITIONS AND METHODS FOR INHIBITING CHEMORESISTANCE IN CANCER AND IMPROVING RESPONSE TO THERAPY

#406

20160046716

2016-02-18

Therapeutic peptides

#407

20160038578

2016-02-11

Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof

#408

20160032007

2016-02-04

Human Antibody Fragments Against Chondroitin Sulfate Proteoglycan 4 (CSPG4)

#409

20160024207

2016-01-28

Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases

#410

20160009815

2016-01-14

Methods for manipulating phagocytosis mediated by CD47

#411

20160009814

2016-01-14

Methods for manipulating phagocytosis mediated by CD47

#412

20160009812

2016-01-14

Specific detection tool for mesenchymal and epithelial-mesenchymal transformed circulating tumor cells

#413

20160008466

2016-01-14

PARTICLE COMPOSITIONS AND METHODS RELATED THERETO

#414

20150374847

2015-12-31

Anti-PMEL17 antibodies and immunoconjugates

#415

20150368343

2015-12-24

Antibody constructs for CDH19 and CD3

#416

20150366957

2015-12-24

Melanoma-Associated MHC Class I Associated Oligopeptides and the Uses Thereof

#417

20150344586

2015-12-03

Disulfide-linked multivalent MHC class I comprising multi-function proteins

#418

20150344551

2015-12-03

Compositions and methods for treatment and detection of cancers

#419

20150322161

2015-11-12

Recombinant human IgM-antibody effective against cancer cells

#420

20150322151

2015-11-12

Antibodies targeting CDH19 for melanoma

#421

20150291698

2015-10-15

Methods and products for preventing and/or treating metastatic cancer

#422

20150290308

2015-10-15

Monoclonal antibodies for CSPG4 for the diagnosis and treatment of basal breast carcinoma

#423

20150274845

2015-10-01

Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of use

#424

20150274839

2015-10-01

Antibodies to non-functional P2X7 receptor

#425

20150246972

2015-09-03

CTLA-4 antibody dosage escalation regimens

#426

20150239976

2015-08-27

Internalizing ErbB2 antibodies

#427

20150216970

2015-08-06

Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors

#428

20150210771

2015-07-30

Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies

#429

20150198598

2015-07-16

Kit for diagnosing malignant melanoma

#430

20150183883

2015-07-02

Anti-ETBR antibodies and immunoconjugates

#431

20150147278

2015-05-28

Antibody against transporter and use thereof

#432

20150132329

2015-05-14

Melanoma antigen peptide and uses thereof

#433

20150119555

2015-04-30

Bispecific antibody molecule

#434

20150118245

2015-04-30

Predictive biomarkers for CTLA-4 blockade therapy and for PD-1 blockade therapy

#435

20150104461

2015-04-16

ANTI-NOTCH2 NRR ANTIBODIES

#436

20150079100

2015-03-19

METHODS OF TREATMENTS USING CTLA-4 ANTIBODIES

#437

20150044704

2015-02-12

Monoclonal antibodies and diagnostic uses thereof

#438

20150044212

2015-02-12

Antibodies Directed to GPNMB and Uses Thereof

#439

20140341916

2014-11-20

THERAPEUTIC COMBINATIONS AND METHODS OF TREATING MELANOMA

#440

20140341902

2014-11-20

Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors

#441

20140322275

2014-10-30

Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor

#442

20140322246

2014-10-30

IgE anti-HMW-MAA antibody

#443

20140316186

2014-10-23

Antibodies to TIP-1

#444

20140242079

2014-08-28

Bispecific T cell activating antigen binding molecules

#445

20140220022

2014-08-07

Method of inhibiting cancer in a mammal by administering an antibody to PTHrP

#446

20140134257

2014-05-15

Methods of treating melanoma

#447

20140134159

2014-05-15

Methods of treating neuroendocrine tumors using frizzled-binding agents

#448

20140099324

2014-04-10

HERV-K antigens, antibodies, and methods

#449

20140037628

2014-02-06

Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

#450

20140010811

2014-01-09

Antibodies to endoplasmin and their use

#451

20140004124

2014-01-02

Monoclonal antibodies for CSPG4 for the diagnosis and treatment of basal breast carcinoma

#452

20130310541

2013-11-21

Use of an anti-Tau pS422 antibody for the treatment of brain diseases

#453

20130295007

2013-11-07

Anti-PMEL17 antibodies and immunoconjugates

#454

20130287798

2013-10-31

Uses of monoclonial antibody 8H9

#455

20130259873

2013-10-03

Methods for treating a tumor using an antibody that specifically binds HMW-MAA

#456

20130259865

2013-10-03

Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof

#457

20130224208

2013-08-29

Methods and drugs targeting Eva1 or Ceacam1 gene expression for treatment and diagnosing of glioma

#458

20130189267

2013-07-25

Means and methods for treating or preventing brain tumors based on the nuclear receptor tailless (TIx)

#459

20130183305

2013-07-18

Cancer therapy using CLDN6 target-directed antibodies in vivo

#460

20130156777

2013-06-20

GLIPR1 INHIBITORS AND THERAPEUTIC USES THEREOF

#461

20130084297

2013-04-04

Anti-ErbB3 antibodies and uses thereof

#462

20130078251

2013-03-28

Anti-MCSP antibodies

#463

20130071398

2013-03-21

Pharmaceutical composition for treating and/or preventing cancer

#464

20130058937

2013-03-07

Bispecific antigen binding molecules

#465

20130058936

2013-03-07

BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE

#466

20130029359

2013-01-31

Monoclonal antibodies and diagnostic uses thereof

#467

20130022597

2013-01-24

Antibodies directed to GPNMB and uses thereof

#468

20120329063

2012-12-27

Means for the diagnosis and therapy of CTCL

#469

20120328555

2012-12-27

Drug delivery of temozolomide for systemic based treatment of cancer

#470

20120321641

2012-12-20

Pharmaceutical composition for treating CAPRIN-1 expressing cancer

#471

20120301476

2012-11-29

Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1

#472

20120277157

2012-11-01

Disease treatment via antimicrobial peptides or their inhibitors

#473

20120244162

2012-09-27

CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS

#474

20120225481

2012-09-06

Non-naturally occurring T cell receptors

#475

20120208774

2012-08-16

METHOD FOR INHIBITING "MELANOMA INHIBITORY ACTIVITY" MIA

#476

20120195855

2012-08-02

METHODS FOR UP-REGULATING ANTIGEN EXPRESSION IN TUMORS

#477

20120171226

2012-07-05

Antibodies to high molecular weight melanoma associated antigen

#478

20120148598

2012-06-14

Methods for treating a tumor using an antibody that specifically binds GRP94

#479

20120128723

2012-05-24

Cancer specific antibody and cell surface proteins

#480

20120122206

2012-05-17

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

#481

20120107321

2012-05-03

Antibodies And Epitopes Specific To Misfolded Prion Protein

#482

20120107306

2012-05-03

Antibodies for epidermal growth factor receptor 3 (HER3)

#483

20120107234

2012-05-03

Pan-HER antibody composition

#484

20120100101

2012-04-26

CTLA-4 antibody dosage escalation regimens

#485

20120059151

2012-03-08

Non-functional P2Xreceptor

#486

20120039915

2012-02-16

Glioblastoma multiforme-reactive antibodies and methods of use thereof

#487

20120039901

2012-02-16

METHOD FOR THE PREVENTION AND TREATMENT OF CANCER BY INHIBITION OF GPVI

#488

20120014948

2012-01-19

Genetic products differentially expressed in tumors and use thereof

#489

20120009194

2012-01-12

Antibodies to endoplasmin and their use

#490

20120003157

2012-01-05

Use of anti-90K monoclonal antibodies for the prevention and treatment of tumors and metastases thereof

#491

20110311521

2011-12-22

Novel therapy for anxiety

#492

20110311450

2011-12-22

POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS

#493

20110294984

2011-12-01

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

#494

20110274617

2011-11-10

Antibody-Targeted Carrier For Contrast Agents

#495

20110256144

2011-10-20

Pharmaceutical composition for treatment and prevention of cancers

#496

20110250211

2011-10-13

Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins

#497

20110218333

2011-09-08

Internalizing ErbB2 antibodies

#498

20110200608

2011-08-18

Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof

#499

20110184041

2011-07-28

PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease

#500

20110171229

2011-07-14

Monoclonal antibodies for CSPG4 for the diagnosis and treatment of basal breast carcinoma

#501

20110158997

2011-06-30

Single chain fragment variable antibody libraries and uses thereof

#502

20110151472

2011-06-23

Means for the diagnosis and therapy of CTCL

#503

20110142825

2011-06-16

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

#504

20110135675

2011-06-09

Melanoma associated peptide analogues and vaccines against melanoma

#505

20110123447

2011-05-26

METHOD OF PROVIDING HUMAN TUMOR-SPECIFIC ANTIBODIES

#506

20110092674

2011-04-21

Non-functional P2Xreceptor

#507

20110059093

2011-03-10

Use of an anti-Tau pS422 antibody for the treatment of brain diseases

#508

20110044993

2011-02-24

METHOD FOR THE PREVENTION AND TREATMENT OF CANCER BY INHIBITION OF GPVI

#509

20110038877

2011-02-17

Antibodies to interleukin-6

#510

20110038873

2011-02-17

Means and methods for treating or preventing brain tumors based on the nuclear receptor tailless (Tlx)

#511

20110014195

2011-01-20

USE OF THERAPEUTIC PEPTIDES FOR THE TREATMENT AND PREVENTION OF CANCER

#512

20110014119

2011-01-20

Methods of treating acute myeloid leukemia by blocking CD47

#513

20100330075

2010-12-30

Monoclonal human tumor-specific antibody

#514

20100310571

2010-12-09

Uses of monoclonal antibody 8H9

#515

20100303816

2010-12-02

Antibodies against human melanoma-associated chondroitin sulphate proteoglycan (MCSP)

#516

20100297150

2010-11-25

DISEASE TREATMENT VIA ANTIMICROBIAL PEPTIDE INHIBITORS

#517

20100284920

2010-11-11

Uses of monoclonal antibody 8H9

#518

20100273705

2010-10-28

Method for inhibiting “melanoma inhibitory activity” MIA

#519

20100254982

2010-10-07

Cancer associated glucose transporter 8 variant

#520

20100226914

2010-09-09

Method for preparation of single chain antibodies

#521

20100221250

2010-09-02

METHODS OF TREATING BRAIN TUMORS WITH ANTIBODIES

#522

20100183615

2010-07-22

CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS

#523

20100158927

2010-06-24

ANTIBODIES, METHODS AND KITS FOR DIAGNOSING AND TREATING MELANOMA

#524

20100150918

2010-06-17

CROSS-SPECIES-SPECIFIC BINDING DOMAIN

#525

20100136518

2010-06-03

Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein

#526

20100111932

2010-05-06

Antibodies against RAMP3

#527

20100080808

2010-04-01

Anti-Notch2 NRR antibodies

#528

20100016571

2010-01-21

Peptide having ability to activate cancer-related gene

#529

20100016559

2010-01-21

Peptide having ability to activate cancer-related gene

#530

20100015624

2010-01-21

Peptide having ability to activate cancer-related gene

#531

20090304690

2009-12-10

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

#532

20090297530

2009-12-03

HERV-K ANTIGENS, ANTIBODIES, AND METHODS

#533

20090252681

2009-10-08

Nanobodies and Polypeptides Against EGFR and IGF-IR

#534

20090232839

2009-09-17

Melanoma associated peptide analogues and vaccines against melanoma

#535

20090232823

2009-09-17

Anti-TYRP1 antibodies

#536

20090192293

2009-07-30

Non-functional P2Xreceptor

#537

20090175877

2009-07-09

METHODS OF INHIBITING METASTASIS

#538

20090117595

2009-05-07

PRIMARY CENTRAL NERVOUS SYSTEM TUMOR SPECIFIC BEHAB ISOFORMS

#539

20090104186

2009-04-23

Melanoma-associated MHC class I associated oligopeptides and the uses thereof

#540

20090098125

2009-04-16

PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease

#541

20090098045

2009-04-16

Cytotoxicity mediation of cells evidencing surface expression of MCSP

#542

20090081215

2009-03-26

Genetic products differentially expressed in tumors and use thereof

#543

20090081214

2009-03-26

GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND USE THEREOF

#544

20090048167

2009-02-19

Disease treatment via antimicrobial peptides or their inhibitors

#545

20080287309

2008-11-20

Methods for Discovering Antibodies Specific to Cancer Cells and Antibodies Discovered Thereby

#546

20080274468

2008-11-06

Means for the diagnosis and therapy of CTCL

#547

20080214791

2008-09-04

Monoclonal antibodies to human high molecular weight-melanoma associated antigen

#548

20080131438

2008-06-05

Antibodies to non-functional P2Xreceptor

#549

20080108135

2008-05-08

Internalizing ErbB2 antibodies

#550

20080095785

2008-04-24

MONOCLONAL ANTIBODIES TO HUMAN HIGH MOLECULAR WEIGHT-MELANOMA ASSOCIATED ANTIGEN

#551

20080019979

2008-01-24

HERV-K Antigens, Antibodies, and Methods

#552

20070297983

2007-12-27

Inhibition of breast carcinoma stem cell growth and metastasis

#553

20070212361

2007-09-13

MONOCLONAL ANTIBODIES TO HUMAN HIGH MOLECULAR WEIGHT-MELANOMA ASSOCIATED ANTIGEN

#554

20070202593

2007-08-30

Cell-Targeted IKB and Methods for the Use Thereof

#555

20070190061

2007-08-16

Peptides for stimulating an immune response against melanoma

#556

20070178098

2007-08-02

Methods of treating cancer comprising administering an interleukin-6 antibody variable region

#557

20070160619

2007-07-12

CTLA-4 antibody dosage escalation regimens

#558

20070141063

2007-06-21

Peptide having ability to activate cancer-related gene

#559

20070105164

2007-05-10

Cancer diagnosis and therapy

#560

20070036797

2007-02-15

Methods of treating brain tumors with antibodies

#561

20060240414

2006-10-26

Genetically engineered glutaminase and its use in antiviral and anticancer therapy

#562

20060223096

2006-10-05

Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function

#563

20060166290

2006-07-27

Primary central nervous system tumor specific BEHAB isoforms

#564

20060128607

2006-06-15

Method for inhibiting "melanoma inhibitory activity" mia

#565

20060115481

2006-06-01

Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy

#566

20060115480

2006-06-01

Disease treatment via antimicrobial peptide inhibitors

#567

20060013817

2006-01-19

Genetic products differentially expressed in tumors and use thereof

#568

20060008901

2006-01-12

Secreted and transmembrane polypeptides and nucleic acids encoding the same

#569

20050271665

2005-12-08

Methods of inhibiting metastasis

#570

20050271653

2005-12-08

Methods and devices for targeting a site in a mammal and for removing species from a mammal

#571

20050260132

2005-11-24

Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta

#572

20050249726

2005-11-10

Reshaped human antibody to human medulloblastoma cells

#573

20050244416

2005-11-03

Bispecific antibody molecule

#574

20050227303

2005-10-13

Method and composition for diagnosis of melanocytic lesions

#575

20050169932

2005-08-04

Uses of monoclonal antibody 8H9

#576

20050164180

2005-07-28

Phage display libraries of human Vfragments

#577

20050163768

2005-07-28

Monoclonal antibodies and their use

#578

20050142062

2005-06-30

Novel method of diagnosing and treating gliomas

#579

20050079605

2005-04-14

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

#580

20050074843

2005-04-07

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

#581

20050074761

2005-04-07

Means for the diagnosis and therapy of CTCL

#582

20050063967

2005-03-24

Cytotoxicity mediation of cells evidencing surface expression of MCSP

#583

20050043512

2005-02-24

Human glioma antigen originating in testis

#584

20050031617

2005-02-10

Antibodies specific for cancer associated antigen SM5-1 and uses thereof